Ксарелто Drug photo

The description is actual on 18.06.2014

  • Latin name: Xarelto
  • ATH code: B01AF01
  • Active ingredient: Rivaroksaban (Rivaroxaban)
  • Producer: Bayer Farma AG., Germany


The tablet of drug contains: rivaroksaban micronized in number of 10, 15 or 20 mg, and auxiliary components: cellulose microcrystallic, croscarmellose sodium, gipromelloza 5cP, lactose monohydrate, magnesium stearate and sodium lauryl sulfate.

The film covering of a cover of a tablet consists from: dye ferrous oxide red, gipromelloza 15cP, titanium dioxide and macrogoal 3350.

Release form

Ksarelto is issued in tablets, film coated with various content of active ingredient. They have the round biconvex form, pink or red-brown color, a bilateral engraving – on the one hand – a triangle and designation of a dosage, and with another the corporate bayerovsky cross is put. On sale packagings from 5 to 100 pieces are offered.

Pharmacological action

The drug inhibiting a factor Ha, anticoagulant of direct action.

Pharmacodynamics and pharmacokinetics

For active agent of this medicine – a rivaroksaban, fast influence, the predictable dozozavisimy answer and high bioavailability is characteristic. At the same time monitoring of parameters of coagulation is not required, there is practically no risk of incompatibility with other food stuffs or medicines.

Medicine is applied as a prophylactic from a stroke at the patients suffering from a ciliary arrhythmia, showing at the same time good efficiency and portability. It is possible to accept this anticoagulant once a day, observing the fixed dose.

Rivaroksaban possesses the high absolute bioavailability making 80–100%. The main component is quickly soaked up with approach of the maximum concentration 2-4 hours later. Getting to an organism, there is a considerable communication of the main part of a rivaroksaban with proteins of a blood plasma, namely plasma albumine. Removal of drug is carried out mainly in the form of metabolites.

Indications to use of medicine of Ksarelto

The main indications are:

  • prevention of a venous thromboembolism, after carrying out large-scale orthopedic operations in the lower extremities;
  • prevention of a stroke and system thromboembolism at fibrillation of auricles of not valve origin and so on.

Contraindications to use

  • the active bleedings affecting especially important bodies, for example, by a gastrointestinal tract, intracranial area and other;
  • the liver diseases accompanied with the coagulopathy causing risk of bleedings;
  • lactation, pregnancy;
  • age of patients, less than 18 years;
  • inborn insufficiency or intolerance of lactase, glyukozo-galaktozny malabsorption;
  • high sensitivity to a rivaroksaban and other excipients.

Side effects

Ksarelto's (Xarelto) treatment can cause various undesirable phenomena mentioning practically all bodies and systems. At the same time often they are shown in moderate degree.

Treat the most widespread side effects:

  • anemia;
  • nausea, transaminases, increase of activity of GGT;
  • hemorrhages after procedures, including postoperative anemia and bleeding from wounds.

Arise slightly less often:

The instruction on Ksarelto (A way and a dosage)

As the application instruction of Ksarelto reports, during prevention of VTE after considerable orthopedic operations to patients appoint daily reception of 10 mg of medicine. Duration of therapy makes 2-5 weeks, depending on scale and complexity of intervention.

This drug is allowed to be accepted at any time, irrespective of the use of food. It is necessary to begin treatment of Xarelto 6-10 hours later after carrying out operation if to reach a hemostasis. In case of the admission of a dosage it is necessary to take immediately Ksarelto's medicine, and the next days it is necessary to continue therapy as usual.


At overdose rivaroksabany the hemorrhagic complications connected with farmakodinamichesky features of drug usually develop. Now the specific antidote of a rivaroksaban is not developed.

For decrease in absorption of a rivaroksaban recommend to accept absorbent carbon within 8 hours.


Simultaneous use of Ksarelto with the strongest inhibitors of an isoenzyme CYP3A4 and P-gp is capable to cause lowering of renal and hepatic clearance that leads to significant increase in system influence and farmakodinamichesky effect of drug.

It is established that Klaritromitsin, Erythromycin and Flukonazol can lead to various changes of concentration of a rivaroksaban, but it is considered order of normal variability and clinically insignificant.

It is necessary to refrain from combined use of a rivaroksaban and a dronedaron as clinical data on such combination are absent.

Ksarelto's reception and rifampicin which belongs to the strong inductors CYP3A4 ip-gp, leads to lowering of farmakodinamichesky effects of drug. Therefore treatment by this drug with other strong inductors needs to be carried out with care.

Terms of sale

Medicine is implemented only according to the recipe.

Storage conditions

It is necessary to store tablets in the place protected from children at a temperature less than 30 °C.

Period of validity

If to meet storage conditions, then it is possible to use drug 3 years.

Analogs of drug of Ksarelto

It is known that Ksarelto's analogs are provided only by his active ingredient or MNN Rivaroksaban – anticoagulant of direct action. Therefore it is considered that it is its main substitute. At the same time the analog price for packaging in 14 pieces makes 1956-2000 rubles.

Ksarelto or Pradaks – what is better?

This question is asked by many patients who are disturbed by a problem of a possible thrombogenesis. As showed the last researches, Ksarelto and Pradaksa possess almost identical efficiency in prevention of formation of blood clots and risk of bleedings at a ciliary arrhythmia. Reception of each of these drugs does not demand a constant control of MNO. At the same time and the cost of these medicines rather high, in comparison with other anticoagulants.

Alcohol and Ksarelto

Clinical trials showed that treatment by this drug is categorically not compatible to alcohol intake as it can lead to development of undesirable effects.


  • Ksarelto of 10 mg No. 10 tabletkibayer Schering Pharma AG
  • Ksarelto of 10 mg No. 5 tabletkibayer Schering Pharma AG
  • Ksarelto of 15 mg No. 100 tabletkibayer Schering Pharma AG
  • Ksarelto of 10 mg No. 30 tabletkibayer Schering Pharma AG
  • Ksarelto of 20 mg No. 28 tabletkibayer Schering Pharma AG

Drugstore of IFC

  • Ksarelto tbl p/pl/o 10 mg No. 30 *, Bayer Consumer/Grenzach Produktionsgermaniya
  • Ksarelto tbl p/pl/o 20 mg No. 14 *, Bayer Consumer/Grenzach Produktionsgermaniya
  • Ksarelto tbl p/pl/o 20 mg No. 28 *, Bayer Consumer/Grenzach Produktionsgermaniya
  • Ksarelto tbl p/pl/o 15 mg No. 28 *, Bayer Consumer/Grenzach Produktionsgermaniya
  • Ksarelto tbl p/pl/o 15 mg No. 14 *, Bayer Consumer/Grenzach Produktionsgermaniya
to show still


  • Ksarelto
  • Ksarelto
  • Ksarelto
  • Ksarelto
  • Ksareltobayer Schering Pharma (Germany)


  • ÈßáÓѽԫ® 10 mg No. 30 tabl.p.p.o.
  • ÈßáÓѽԫ® 10 mg No. 10 tabl.p.p.o.
  • ÈßáÓѽԫ® 20 mg No. 100 tabl.p.p.o.
  • ÈßáÓѽԫ® 20 mg No. 28 tabl.p.p.o.
  • ÈßáÓѽԫ® 15 mg No. 42 tabl.p.p.o.
to show still
Section: Cardiological Cardiovascular
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use of Ksarelto surely consult with the attending physician.